Skip to main content
. 2014 Aug;58(8):4804–4813. doi: 10.1128/AAC.03145-14

TABLE 1.

Anti-HIV-1 activity of NRTI, NNRTI, or the integrase inhibitora

Drug Jurkat cells
MT-4 cells
MDM cells
CD4+ T cells
EC50 (μM)
FC EC50 (μM)
FC EC50 (μM)
FC EC50 (μM)
FC
−Vpx +Vpx −Vpx +Vpx −Vpx +Vpx −Vpx +Vpx
AZT 0.023 0.034 1 0.017 0.082 5 0.015 0.389 26 0.068 4.607 67
d4T 5.000 4.300 1 0.962 2.376 2 0.300 2.009 7 1.245 1/>5b 1/>4b
3TC 0.164 0.156 1 0.816 0.758 1 0.081 0.022 1 0.524 0.372 1
ddC 0.052 0.059 1 0.292 0.308 1 0.113 0.042 1 0.115 0.081 1
ABC 0.053 0.059 1 0.001 0.001 1 0.003 0.003 1 0.015 0.009 1
TFV 11.598 10.858 1 2.877 2.162 1 6.114 5.599 1 1.949 6.822 3
ddI 2.045 2.572 1 1.470 2.692 2 1.805 2.251 1 0.402 0.481 1
NVP 0.090 0.095 1 0.237 0.295 1 0.274 0.361 1 1.017 1.256 1
EFV 0.038 0.072 2 0.047 0.055 1 0.071 0.071 1 0.068 0.091 1
RAL 0.003 0.007 3 0.005 0.004 1 0.022 0.031 1 0.017 0.015 1
a

NRTI are AZT, d4T, 3TC, ddC, TFV, ddI, and ABC; NNRTI are NVP and EFV; the integrase inhibitor is RAL. EC50 values were calculated in T cell lines negative or expressing low levels of SAMHD1 (Jurkat and MT4) and primary cells MDM and CD4+ T cells. EC50, effective concentration required to block HIV-1 replication by 50%; FC, fold change or ratio of the EC50 with Vpx (+) and the EC50 without Vpx (−). Results are the means from at least two independent experiments done in triplicates.

b

EC50 > 5 μM in 2/5 donors, which resulted in a fold change of <4.